Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMAG NASDAQ:BCRX NASDAQ:CLDX NASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMAGAMAG Pharmaceuticals$13.75$13.74$4.41▼$13.80$477.47M0.89950,664 shsN/ABCRXBioCryst Pharmaceuticals$8.29$8.57$6.01▼$11.31$1.74B1.132.21 million shs3.93 million shsCLDXCelldex Therapeutics$23.61+7.0%$22.37$14.40▼$47.00$1.47B1.191.46 million shs1.60 million shsMNKDMannKind$5.51-4.0%$3.93$3.38▼$7.63$1.41B1.023.80 million shs8.99 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMAGAMAG Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BCRXBioCryst Pharmaceuticals0.00%-2.70%-5.04%-24.50%+0.48%CLDXCelldex Therapeutics+7.03%+4.47%+8.30%+20.89%-43.11%MNKDMannKind-4.01%+21.90%+40.56%+28.14%-9.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMAGAMAG PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABCRXBioCryst Pharmaceuticals4.0885 of 5 stars3.51.00.04.23.12.50.6CLDXCelldex Therapeutics2.1396 of 5 stars3.43.00.00.03.50.00.0MNKDMannKind4.116 of 5 stars3.63.00.00.03.21.73.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMAGAMAG Pharmaceuticals 0.00N/AN/AN/ABCRXBioCryst Pharmaceuticals 2.90Moderate Buy$16.70101.45% UpsideCLDXCelldex Therapeutics 2.78Moderate Buy$46.6797.66% UpsideMNKDMannKind 3.29Buy$10.0081.49% UpsideCurrent Analyst Ratings BreakdownLatest AMAG, BCRX, CLDX, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025MNKDMannKindWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$9.00 ➝ $10.009/2/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $11.008/26/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$7.00 ➝ $8.008/25/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.008/20/2025CLDXCelldex TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$44.00 ➝ $38.008/20/2025CLDXCelldex TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$56.00 ➝ $48.008/20/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $62.008/20/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $42.008/7/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $7.008/4/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.007/23/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $8.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMAGAMAG Pharmaceuticals$327.75M1.46N/AN/A$7.37 per share1.87BCRXBioCryst Pharmaceuticals$450.71M3.86N/AN/A($2.01) per share-4.12CLDXCelldex Therapeutics$7.02M223.35N/AN/A$9.87 per share2.39MNKDMannKind$285.50M5.92$0.17 per share33.07($0.18) per share-30.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMAGAMAG Pharmaceuticals-$466.46M-$6.88N/A76.39N/A-74.93%-16.92%-5.96%N/ABCRXBioCryst Pharmaceuticals-$88.88M-$0.18N/AN/A1.89-6.41%N/A-1.78%11/3/2025 (Estimated)CLDXCelldex Therapeutics-$157.86M-$3.01N/AN/AN/A-3,446.88%-27.61%-26.20%11/5/2025 (Estimated)MNKDMannKind$27.59M$0.1150.1023.96N/A10.87%-32.60%7.81%11/6/2025 (Estimated)Latest AMAG, BCRX, CLDX, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CLDXCelldex Therapeutics-$0.86-$0.85+$0.01-$0.85$1.13 million$0.73 million8/6/2025Q2 2025MNKDMannKind$0.04$0.05+$0.01N/A$77.82 million$76.53 million8/4/2025Q2 2025BCRXBioCryst Pharmaceuticals$0.03$0.15+$0.12$0.02$149.59 million$163.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMAGAMAG PharmaceuticalsN/AN/AN/AN/AN/ABCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMAGAMAG Pharmaceuticals1.131.751.45BCRXBioCryst PharmaceuticalsN/A2.252.22CLDXCelldex TherapeuticsN/A19.6719.67MNKDMannKindN/A2.502.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMAGAMAG PharmaceuticalsN/ABCRXBioCryst Pharmaceuticals85.88%CLDXCelldex TherapeuticsN/AMNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipAMAGAMAG Pharmaceuticals12.73%BCRXBioCryst Pharmaceuticals5.10%CLDXCelldex Therapeutics4.40%MNKDMannKind3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMAGAMAG Pharmaceuticals44034.73 millionN/AOptionableBCRXBioCryst Pharmaceuticals530209.92 million199.21 millionOptionableCLDXCelldex Therapeutics15066.41 million63.49 millionOptionableMNKDMannKind400306.83 million297.62 millionOptionableAMAG, BCRX, CLDX, and MNKD HeadlinesRecent News About These CompaniesMannKind (NASDAQ:MNKD) Shares Gap Up on Analyst Upgrade57 minutes ago | americanbankingnews.comPositive TETON-2 Study Results Drive Buy Rating and Price Target Increase for MannKindSeptember 2 at 9:51 AM | tipranks.comUnited Therapeutics succeeds in late-stage trial for Tyvaso against lung disorderSeptember 2 at 8:47 AM | msn.comWellington Management Group LLP Reduces Stock Position in MannKind Corporation $MNKDSeptember 1 at 3:52 AM | marketbeat.comRussell Investments Group Ltd. Cuts Position in MannKind Corporation $MNKDSeptember 1 at 3:41 AM | marketbeat.comMannKind (NASDAQ:MNKD) Stock Price Up 10.4% on Analyst UpgradeAugust 29, 2025 | marketbeat.comInvesco Ltd. Grows Position in MannKind Corporation $MNKDAugust 29, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Shares Up 10.4% Following Analyst UpgradeAugust 29, 2025 | americanbankingnews.comMannKind to Present at Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comMannKind (NASDAQ:MNKD) Stock Price Down 5.2% - Here's What HappenedAugust 27, 2025 | marketbeat.comMannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled TherapyAugust 27, 2025 | markets.businessinsider.comMannKind Corporation Collaborates with United Therapeutics to Develop Second Dry Powder Inhalation TherapyAugust 27, 2025 | quiverquant.comQMannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled TherapyAugust 27, 2025 | globenewswire.comNew Strong Sell Stocks for August 27thAugust 27, 2025 | zacks.comMannKind (NASDAQ:MNKD) Price Target Raised to $8.00August 27, 2025 | americanbankingnews.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPHAugust 26, 2025 | businesswire.comVanguard Group Inc. Acquires 1,263,622 Shares of MannKind Corporation $MNKDAugust 26, 2025 | marketbeat.comMannKind Corporation (MNKD) Mergers and Acquisition Call TranscriptAugust 25, 2025 | seekingalpha.comMannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million DealAugust 25, 2025 | benzinga.comMannKind’s Strategic Acquisition of scPharmaceuticals: A Catalyst for Future Growth and Value CreationAugust 25, 2025 | tipranks.comMannKind (MNKD) to Acquire scPharmaceuticals for $360 MillionAugust 25, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMAG, BCRX, CLDX, and MNKD Company DescriptionsAMAG Pharmaceuticals NASDAQ:AMAGAMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.BioCryst Pharmaceuticals NASDAQ:BCRX$8.29 0.00 (0.00%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$8.25 -0.04 (-0.48%) As of 09/3/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Celldex Therapeutics NASDAQ:CLDX$23.61 +1.55 (+7.03%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$23.64 +0.04 (+0.15%) As of 09/3/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.MannKind NASDAQ:MNKD$5.51 -0.23 (-4.01%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$5.48 -0.04 (-0.64%) As of 09/3/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
